Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Other Non-Current Liabilities (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Other Non-Current Liabilities for 9 consecutive years, with $973000.0 as the latest value for Q1 2026.

  • For Q1 2026, Other Non-Current Liabilities fell 12.81% year-over-year to $973000.0; the TTM value through Mar 2026 reached $973000.0, down 12.81%, while the annual FY2025 figure was $1.0 million, 7.94% down from the prior year.
  • Other Non-Current Liabilities hit $973000.0 in Q1 2026 for Bicycle Therapeutics, down from $1.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $6.0 million in Q3 2024 and bottomed at $973000.0 in Q1 2026.
  • Average Other Non-Current Liabilities over 5 years is $3.1 million, with a median of $3.4 million recorded in 2022.
  • Year-over-year, Other Non-Current Liabilities skyrocketed 38.16% in 2024 and then crashed 81.67% in 2025.
  • Bicycle Therapeutics' Other Non-Current Liabilities stood at $3.8 million in 2022, then rose by 19.59% to $4.6 million in 2023, then tumbled by 75.52% to $1.1 million in 2024, then fell by 7.94% to $1.0 million in 2025, then fell by 5.72% to $973000.0 in 2026.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $973000.0, $1.0 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.